In a Lewis lung cancer model, CCR2 knockout or the CCR2 inhibitor RS504393 reduced TAM recruitment, shifted TAMs to an M1 phenotype, and suppressed angiogenesis and tumor progression (22). Here, CCR2 is linked to neoplasm.